Results 41 to 50 of about 14,917 (287)
Frontiers in Pharmacology, 2022 Background and purpose: The TASTE trial indicated that patients with acute ischemic stroke (AIS) using edaravone dexborneol have a significantly higher proportion of 90-day good functional outcomes (mRS 0–1) than those using edaravone.
Fenghao Shi +8 more
doaj +1 more source
Molecular Pharmaceutics, 2023 Preparation of the ionic liquid (IL) form of active pharmaceutical ingredients (APIs), termed API-IL, has attracted attention because it can improve upon certain disadvantages of APIs, such as poor water solubility and low stability.
T. Fukuta, Mayumi Ikeda-Imafuku, Y. Iwao
semanticscholar +1 more source
Current Issues in Molecular Biology, 2023 The appropriate dosage of edaravone—a radioprotective agent—and its effect on tumors are unknown. This study evaluated the effects of edaravone on intestinal injuries and tumors in mice induced by whole body X-ray irradiation.
Terufumi Kawamoto, Keisuke Sasai
doaj +1 more source
Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke
Stroke, 2021 Supplemental Digital Content is available in the text. Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant
Jie Xu +20 more
semanticscholar +1 more source
Medicine, 2023 Background: Shuxuening injection (SXN) is a traditional Chinese medicine used in the treatment of cardiovascular diseases. Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined.
Liang-Da Li, Yue Zhou, Shan-Fen Shi
openaire +2 more sources
Efficacy of Edaravone in Cardioembolic Stroke
Internal Medicine, 2006 We investigated the efficacy of edaravone in patients with cardioembolic stroke.Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) for 7 days, and were retrospectively compared with a historical-controlled cohort of similar patients (control group, n=114).Early improvement (between day 0 and day 10),
Teruyuki Hirano +6 more
openaire +4 more sources
Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats [PDF]
, 2013 Oxidative stress is implicated as an important factor in the development of Alzheimer's disease (AD). In the present study, we have investigated the effects of edaravone (9mg/kg, 3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, in a ...
Chi, Lijun +6 more
core +1 more source
Neurological Sciences, 2023 Aim The study aims to increase understanding of edaravone’s efficacy and safety as an amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this field’s future research.
Anas Zakarya Nourelden +7 more
semanticscholar +1 more source
Pharmaceuticals, 2021 Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare.
Hideki Houzen +5 more
doaj +1 more source
Molecules, 2023 Edaravone, acting as a cerebral protective agent, is administered to treat acute brain infarction. Its poor solubility is addressed here by means of optimizing the composition of the aqueous choline chloride (ChCl)-based eutectic solvents prepared with ...
P. Cysewski +2 more
semanticscholar +1 more source